Top-Rated StocksTop-RatedNASDAQ:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $20.09 +0.53 (+2.71%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$19.90 -0.19 (-0.95%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vor Biopharma Stock (NASDAQ:VOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vor Biopharma alerts:Sign Up Key Stats Today's Range$19.57▼$20.3050-Day Range$18.03▼$25.1052-Week Range$6.50▼$26.00Volume407,724 shsAverage Volume738,192 shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$38.29Consensus RatingBuy Company Overview Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33. These programs have been developed primarily for acute myeloid leukemia (AML); neither is an approved treatment. Founded in 2015 and based in Cambridge, Massachusetts, Vor has focused its clinical development and research on cancer therapies. Its work has been centered on the U.S. biotechnology and clinical-research landscape.AI Generated. May Contain Errors. Read More Vor Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreVOR MarketRank™: 2.475396929535 of 5 starsVor Biopharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 597th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingVor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialVor Biopharma has a consensus price target of $38.29, representing about 90.6% upside from its current price of $20.09.Amount of Analyst CoverageVor Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Vor Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vor Biopharma are expected to decrease in the coming year, from ($2.74) to ($3.65) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.25% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 9.88.Change versus previous monthShort interest in Vor Biopharma has recently increased by 0.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.87 News SentimentVor Biopharma has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vor Biopharma this week, compared to 3 articles on an average week.Search Interest2 people have searched for VOR on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.27% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VOR Stock News HeadlinesVor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise1 hour ago | globenewswire.comVor Biopharma (VOR) Stock Looks Reasonable After a 94% Five Year SlideNovember 6, 2026 | finance.yahoo.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 12 at 1:00 AM | USA Capital Gold (Ad)HC Wainwright Forecasts Stronger Earnings for Vor BiopharmaNovember 6, 2026 | americanbankingnews.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 4, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Vor Biopharma (VOR)November 3, 2026 | theglobeandmail.comVor Biopharma (NASDAQ:VOR) Rating Lowered to "Sell" at Wall Street ZenNovember 2, 2026 | americanbankingnews.comVor Biopharma Q3 Loss NarrowsOctober 30, 2026 | finance.yahoo.comSee More Headlines VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $13.08 at the beginning of 2026. Since then, VOR stock has increased by 53.6% and is now trading at $20.09. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NASDAQ:VOR) issued its quarterly earnings results on Friday, October, 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.64. When did Vor Biopharma's stock split? Shares of Vor Biopharma reverse split before market open on Thursday, September 18th 2025.The 1-20 reverse split was announced on Thursday, September 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $167 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 9,828,017 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO. Who are Vor Biopharma's major shareholders? Top institutional shareholders of Vor Biopharma include State Street Corp (3.21%), Nan Fung Trinity HK Ltd. (1.17%), Alps Advisors Inc. (0.13%) and Profund Advisors LLC (0.03%). Insiders that own company stock include Ra Capital Management, LP and Reprogrammed Interchange Llc. View institutional ownership trends. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vor Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vor Biopharma investors own include NVIDIA (NVDA), Definium Therapeutics (DFTX), Advanced Micro Devices (AMD), Biomea Fusion (BMEA), Plug Power (PLUG), Super Micro Computer (SMCI) and BigBear.ai (BBAI). Company Calendar Last Earnings10/30/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VOR's financial health is in the Green zone, according to TradeSmith. VOR has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VOR Previous SymbolNASDAQ:VOR CIK1817229 Webvorbio.com Phone(617) 655-6580FaxN/AEmployees76Year Founded2016Price Target and Rating Average Price Target for Vor Biopharma$38.29 High Price Target$50.00 Low Price Target$27.00 Potential Upside/Downside+90.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,430,000Free Float61,268,000Market Cap$1.23 billion OptionableOptionable Beta1.87 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:VOR) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
